Three cycles of ABDV plus extended field radiotherapy in patients with poor prognosis early-intermediate stage Hodgkin's disease

Vito Lorusso, Autur Timurian, Mario Brandi, Antonio Pellecchia, Antonio Cramarossa, Franco Marzullo, Mario De Lena

Research output: Contribution to journalArticle

Abstract

The aim of the study was to verify the possibility of treating patients with poor prognosis early-intermediate Hodgkin's disease with a combined modality therapy consisting of three cycles of ABVD followed by extended field irradiation (EFRT). No patient had bulky mediastinum or had previously been administered chemo- or radiotherapy. At pathological restaging, 40/44 (91%) evaluable patients achieved complete responses (CR). After a ten-year follow-up, freedom from progression (FFP), relapse-free survival (RFS) and overall survival (OS) were 80%, 83% and 81%, respectively. Of the prognostic factors, univariate analysis showed that only stage III negatively influenced RFS, but not OS. Toxicity was mild except for subclinical mediastinal fibrosis in 32.5% of CR patients. No patient reported reduced fertility. Two cases of second neoplasms were recorded: one ameboid glioma and one thymoma, both occurring within five years after discontinuing chemo-radiotherapy. Our data suggest that three cycles of ABVD preceding EFRT is an effective treatment for poor prognosis early-intermediate stage Hodgkin's disease; nevertheless, stage III patients and some stage II patients with unfavorable prognostic factors should be treated with a more aggressive approach.

Original languageEnglish
Pages (from-to)669-674
Number of pages6
JournalInternational Journal of Oncology
Volume8
Issue number4
Publication statusPublished - Apr 1996

    Fingerprint

Keywords

  • Chemotherapy
  • Hodgkin's disease
  • Radiotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Lorusso, V., Timurian, A., Brandi, M., Pellecchia, A., Cramarossa, A., Marzullo, F., & De Lena, M. (1996). Three cycles of ABDV plus extended field radiotherapy in patients with poor prognosis early-intermediate stage Hodgkin's disease. International Journal of Oncology, 8(4), 669-674.